Results 41 to 50 of about 562,936 (248)

Dysfunctional endocannabinoid CB1 receptor expression and signaling contribute to skeletal muscle cell toxicity induced by simvastatin

Cell Death and Disease, 2023
Statins are the most prescribed lipid-lowering agents worldwide. Their use is generally safe, although muscular toxicity occurs in about 1 in 10.000 patients.
Hilal Kalkan, Elisabetta Panza, Ester Pagano, Giuseppe Ercolano, Claudia Moriello, Fabiana Piscitelli, Mónika Sztretye, Raffaele Capasso, Vincenzo Di Marzo, Fabio Arturo Iannotti   +9 more
doaj   +1 more source

Expression of cannabinoid 1 and, 2 receptors and the effects of cannabinoid 1 and, 2 receptor agonists on detrusor overactivity associated with bladder outlet obstruction in rats

BMC Urology, 2017
Background This study investigated changes in the expression of cannabinoid (CB) receptors and the effects of CB1 and CB2 agonists on detrusor overactivity (DO) associated with bladder outlet obstruction (BOO) in rats.
Sung Dae Kim, Kang Jun Cho, Joon Chul Kim   +2 more
doaj   +1 more source

Involvement of the CB2 cannabinoid receptor in cell growth inhibition and G0/G1 cell cycle arrest via the cannabinoid agonist WIN 55,212–2 in renal cell carcinoma

BMC Cancer, 2018
Background The anti-tumor properties of cannabinoids have been investigated in many in vitro and in vivo studies. Many of these anti-tumor effects are mediated via cannabinoid receptor types 1 and 2 (CB1 and CB2), comprising the endocannabinoid system ...
Mohammed I. Khan, Anna A. Sobocińska, Klaudia K. Brodaczewska, Katarzyna Zielniok, Malgorzata Gajewska, Claudine Kieda, Anna M. Czarnecka, Cezary Szczylik   +7 more
doaj   +1 more source

Targeting cannabinoid CB2 receptors in the Central Nervous System. Medicinal chemistry approaches with focus on neurodegenerative disorders

Frontiers in Neuroscience, 2016
Endocannabinoids activate two types of specific receptors, namely cannabinoid CB1 and CB2. Contrary to the psychotropic actions of agonists of CB1 receptors, and serious side effects of the selective antagonists of this receptor, drugs acting on CB2 ...
Gema Navarro, Paula Morales, Carmen Rodríguez-Cueto, Javier Fernández-Ruiz, Nadine Jagerovic, Rafael Franco   +5 more
doaj   +1 more source

Cannabinoid receptor expression in non-small cell lung cancer. Effectiveness of tetrahydrocannabinol and cannabidiol inhibiting cell proliferation and epithelial-mesenchymal transition in vitro.

PLoS ONE, 2020
BACKGROUND/OBJECTIVE:Patients with non-small cell lung cancer (NSCLC) develop resistance to antitumor agents by mechanisms that involve the epithelial-to-mesenchymal transition (EMT).
Lara Milian, Manuel Mata, Javier Alcacer, María Oliver, María Sancho-Tello, José Javier Martín de Llano, Carlos Camps, José Galbis, Julian Carretero, Carmen Carda   +9 more
doaj   +1 more source

The orexigenic effect of ghrelin is mediated through central activation of the endogenous cannabinoid system [PDF]

, 2008
INTRODUCTION: Ghrelin and cannabinoids stimulate appetite, this effect possibly being mediated by the activation of hypothalamic AMP-activated protein kinase (AMPK), a key enzyme in appetite and metabolism regulation. The cannabinoid receptor type 1 (CB1)
Judith Harvey-White, Francesca Lolli, Farkas, I., Amin, F., Mirjam Christ-Crain, Kola, Blerina, Fekete, Csaba, George Kunos, Kola, B., Faisal Amin, A. B. Grossman, M. Korbonits, Blerina Kola, Liposits, Zsolt, G. Kunos, Ashley B Grossman, B. Kola, Amin, F, Gábor Wittmann, Kunos, George, Christ-Crain, M, Farkas, Imre, Lolli, F, Zsolt Liposits, Lolli, F., F. Amin, Farkas, I, Christ-Crain, M., Korbonits, M., I. Farkas, Grossman, AB, C. Fekete, Kola, B, Harvey-White, J., Wittmann, Gábor, Korbonits, Márta, G. Wittmann, Harvey-White, J, Fekete, C, Harvey-White, Judith, Márta Korbonits, Imre Farkas, Liposits, Z, Z. Liposits, Grossman, Ashley B., Ashley B. Grossman, Wittmann, G., Christ-Crain, Mirjam, Amin, Faisal, Lolli, Francesca, Liposits, Z., M. Christ Crain, J. Harvey White, Fekete, C., Korbonits, M, Kunos, G., Csaba Fekete, Grossman, A. B., Kunos, G, Wittmann, G   +59 more
core   +3 more sources

Quinazoline-2,4(1H,3H)-dione derivatives as new class of CB1 Agonists: A pharmacophore-based virtual screening workflow and Lead discovery [version 1; peer review: 2 approved]

F1000Research
Background The cannabinoid 1 (CB1) receptor is the primary target of Δ9-tetrahydrocannabinol (Δ9-THC), the psychoactive component of cannabis sativa (commonly known as “kif” in Morocco).
Fouad Khalil, Abdellah EL AISSOUQ, MOURAD STITOU, Mohamed Enneiymy, Said El Rhabori, Hicham Zaitan, Abdelkrim Ouammou   +6 more
doaj   +1 more source

Absence of Entourage: Terpenoids Commonly Found in Cannabis sativa Do Not Modulate the Functional Activity of Δ9-THC at Human CB1 and CB2 Receptors

bioRxiv, 2019
Introduction: Compounds present in Cannabis sativa such as phytocannabinoids and terpenoids may act in concert to elicit therapeutic effects. Cannabinoids such as Δ9-tetrahydrocannabinol (Δ9-THC) directly activate cannabinoid receptor 1 (CB1) and ...
Marina J. Santiago, Shivani Sachdev, J. Arnold, I. McGregor, M. Connor   +4 more
semanticscholar   +1 more source

Altered Expression of the CB1 Cannabinoid Receptor in the Triple Transgenic Mouse Model of Alzheimer's Disease [PDF]

, 2014
The endocannabinoid system has gained much attention as a new potential pharmacotherapeutic target in various neurodegenerative diseases, including Alzheimer's disease (AD).
Silvia Cianci, ROMANO, ADELE, Romano, A, M. r. Elphick, Gianluigi Vendemiale, Pace, Lorenzo, Elphick, Maurice R, Bedse, G, Angelo M. Lavecchia, Gaurav Bedse, GAETANI, SILVANA, VENDEMIALE, GIANLUIGI, LAVECCHIA, ANGELO MICHELE, @CORRESPONDING AUTHOR, Vendemiale, G, CIANCI, SILVIA, Pace Lorenzo, Lorenzo Federico Pace, Adele Romano, Gaetani, S, Tommaso Cassano, BEDSE, GAURAV, Lorenzo, P, Caterina Grillo, Cassano, T, Grillo, C, Laferla, Frank M, ALTIERI, Fabio, Elphick, MR, LaFerla, FM, Maurice R. Elphick, GRILLO, CATERINA, Silvana Gaetani, Frank M. LaFerla, F. m. Laferla, CASSANO, TOMMASO, Lavecchia, AM, Fabio Altieri, Altieri, F, Cianci, S   +39 more
core   +1 more source

Antagonism of CB1‐mediated discriminative‐stimulus effects by CB1 neutral and inverse‐agonist antagonists

The FASEB Journal, 2012
CB1 inverse‐agonist antagonists (e.g., rimonabant) have behavioral effects that limit their clinical utility. Recent data suggest that CB1 neutral antagonists may not have rimonabant‐like effects, raising the possibility of improved clinical utility. The present studies were conducted to compare how inverse‐agonist antagonists (SR141716A, AM 6538) and ...
Brian D. Kangas, Kiran Vemuri, Ganesh Thakur, Alex Makriyannis, Jack Bergman   +4 more
openaire   +1 more source